Retroviral Surface Display Using Mutated Envelopes for T Cell Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for screening challenging cell types, such as T cells, and delivering nucleic acids to target cells in a specific manner are inefficient and require significant effort, particularly in determining T cell receptor specificity.
Innovation Solution
Retroviruses are engineered with mutated envelope proteins and non-viral membrane-bound proteins with extracellular targeting domains to enable targeted entry into specific cells, allowing for efficient screening and delivery of nucleic acids without recombinant TCR expression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If recombinant expression of T cell receptors is used for screening, then specificity is improved, but device complexity and manufacturing difficulty increase
Solution Approach 1:
The patent extracts the essential function of T cell recognition by displaying peptide-MHC complexes on the viral envelope surface, removing the need for recombinant TCR expression in target cells. This extraction of the recognition mechanism from complex cellular systems to a simplified viral display system resolves the contradiction between specificity and complexity.
Solution Approach 2:
The patent introduces a peptide-MHC complex displayed on the viral envelope as an intermediary that mediates specific recognition between the virus and T cells. This intermediary enables specific targeting without requiring recombinant TCR expression, thus maintaining specificity while reducing system complexity.
2Productivity
If traditional screening methods are used for challenging cell types, then ease of operation is maintained, but productivity decreases
Solution Approach 1:
The patent creates a universal viral display platform that can screen multiple ligands and target various cell types simultaneously. The pseudotyped virus system with peptide-MHC display can be applied to screen T cell repertoires, identify antigen-specific cells, and deliver nucleic acids across different cell types, achieving high throughput without sacrificing operational simplicity.
Solution Approach 2:
The patent replaces complex mechanical and procedural screening methods with a biological recognition system. Instead of using sophisticated instrumentation and complex protocols for cell screening, the system uses natural virus-cell interaction mechanisms modified with peptide-MHC display, enabling high-throughput screening through simple incubation and detection procedures.
3Adaptability or versatility
If native viral envelope proteins are used, then ease of manufacture is improved, but adaptability decreases
Solution Approach 1:
The patent segments the viral envelope protein into functional domains: a pseudotype backbone for manufacturing and a removable peptide-MHC display domain for adaptability. This segmentation allows the use of well-established pseudotyped virus production methods while incorporating customizable targeting sequences, resolving the contradiction between ease of manufacture and adaptability.
Solution Approach 2:
The patent creates a composite viral envelope structure combining a stable pseudotype backbone (for ease of manufacture) with customizable peptide-MHC display elements (for adaptability). This composite approach allows the virus to retain the production advantages of pseudotyped systems while gaining the targeting flexibility needed for specific cell type recognition and high-throughput screening.
Data Source
AI summary
Compositions of retroviruses and methods of using the same for gene delivery are disclosed, wherein the retroviruses comprise a viral envelope protein comprising at least one mutation that diminishes its native function, a non-viral membrane-bound protein comprising a membrane-bound domain and an extracellular targeting domain.